Knowing what to test beyond A1c is what separates a longevity-grade prediabetes workup from a population screen. The gap between the two is where years of insulin resistance hide. A1c is a three-month average of blood sugar and a late indicator. By the time it crosses the prediabetes threshold, the insulin resistance driving it has often been building for years. This guide walks through the markers that catch the process earlier, what each one adds to the picture and why the testing cadence matters as much as the test list.

Key takeaways
  • A1c is a lagging population screen that misses insulin resistance in a meaningful share of people.
  • Fasting insulin and HOMA-IR catch the compensation phase years before A1c moves.
  • ApoB, Lp(a) and hs-CRP read the cardiovascular damage insulin resistance drives alongside it.
  • Hormone and thyroid panels matter here because insulin resistance does not act alone.
  • Four audits a year at $299 a month is the cadence the biomarkers actually move on.

Why A1c alone is not the real answer

A1c estimates average blood sugar over roughly three months and it is the test the system defaults to because it is cheap and standard. Its weakness is timing. Blood sugar stays normal for years while insulin works overtime to hold it there, which means a normal A1c can coexist with significant insulin resistance. The CDC's prediabetes estimates place more than a third of American adults in the prediabetes range and most of them do not know it, which is exactly what a screen that catches the process late would predict.

The compensation phase is the window that matters. Insulin rises to hold blood sugar flat and the person wearing that pattern feels it as fatigue after meals, stubborn weight, rising triglycerides and blood pressure drifting upward rather than as anything a standard panel would flag. Reading only A1c means waiting for the decompensation to show up in the average before acting on it.

The markers that catch the process earlier

Fasting insulin. The single most informative early marker and the one most standard panels leave off. Elevated fasting insulin with normal glucose is the compensation phase itself, visible years before A1c moves.

HOMA-IR. A calculation from fasting insulin and fasting glucose that quantifies insulin resistance on a continuous scale, which makes trend readings possible across audits rather than a single threshold judgment.

ApoB. Insulin resistance drives the liver to package more atherogenic particles, so ApoB tends to rise alongside it even when LDL cholesterol looks acceptable. Reading them together is how a longevity panel catches the cardiovascular damage running parallel to the metabolic one.

Lp(a). Genetically fixed and unaffected by lifestyle, which is precisely why it belongs in the first panel. It changes how aggressively everything else is treated and it never appears on a standard screen.

hs-CRP. The inflammation marker that rises with visceral fat and insulin resistance, giving the metabolic process a cardiovascular readout in the same tube of blood.

HbA1c and the lipid panel. Still worth reading, both as the population-standard anchor and as the trend line to compare against.

What each prediabetes-lane marker adds

MarkerWhat it catchesWhy a standard panel misses it
Fasting insulinThe compensation phase itselfRarely ordered without symptoms
HOMA-IRInsulin resistance on a continuous scaleRequires insulin to be drawn first
ApoBParticle count driven by insulin resistanceReplaced by LDL cholesterol on standard panels
Lp(a)Genetically fixed cardiovascular riskOne-time test, almost never screened
hs-CRPInflammation from visceral fat and insulin resistanceNot part of routine screens
HbA1cThe three-month average, late but standardIt is the standard, which is the problem

Why hormones and thyroid belong in the same panel

Insulin resistance does not act alone. Thyroid dysfunction changes metabolic rate and lipid handling. Cortisol patterns shift with poor sleep and chronic stress and they move glucose and visceral fat with them. Sex hormones change body composition and insulin sensitivity in both directions and midlife hormone shifts in women are one of the most common untold stories behind a rising A1c. A panel that reads the metabolic lane while ignoring the hormonal one produces half a diagnosis, which is why our Biomarker Audit runs the full hormone and thyroid picture in the same draw.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

Cadence is the other half of the answer

A panel this deep once a decade is trivia. The biomarkers that matter move on a scale of months and the value of a marker lies in its trend rather than its snapshot. Annual physicals read a quarterly problem once a year, which is management by calendar rather than by evidence.

Our model puts four comprehensive audits a year inside a flat $299 monthly fee, with a two month commitment at the start paid as a single $598 charge covering the first two months together. From month three it is month to month and you can cancel anytime after that commitment. The audit reads fasting insulin, HOMA-IR, HbA1c, the full lipid panel with ApoB, Lp(a), hs-CRP and the full hormone and thyroid panels, all through the Beluga Health lab network, with additional labs beyond the quarterly cadence billed at pass-through cost.

The question worth asking at any lab-based program

Who reads these labs with me, how often and against what threshold for action? A panel nobody reads quarterly is a PDF, not a program.

Who delivers the care

Clinical care is delivered by physicians of Beluga Health, P.A., an independent Florida professional corporation licensed in all 50 states, working under GoodLife Health's clinical protocols. Medication, whether a branded GLP-1 or a thyroid or hormone prescription, is a separate charge billed by the pharmacy at its own price with zero markup, so nothing on our side earns a dollar from the prescribing that follows the labs.

What the compensation phase actually feels like

The markers are the evidence and the symptoms are what bring people to ask the question in the first place and in the insulin resistance lane those symptoms have a signature worth naming. Post-meal fatigue that arrives within an hour of eating and is different from ordinary tiredness. An afternoon energy dip that food makes worse rather than better. Cravings that cluster in the evening and respond to nothing willpower-based, because the driver is hormonal rather than moral. Weight that settles at the waist and resists everything that worked at thirty. Triglycerides that creep upward on annual draws while every other number stays technically fine and a blood pressure that drifts with them.

None of these is a diagnosis on its own and none should be treated as one, which is exactly why the panel exists. But the pattern in aggregate is the thing the compensation phase produces and the patients who carry it usually spend years being told their labs are normal. They were normal. They were also a snapshot of a system compensating successfully, taken once a year by a screen designed to catch failure rather than to watch a process.

The fasting insulin reading is what converts that experience from a vague complaint into a measurement. When fasting insulin runs high while glucose runs normal, the patient's years of dismissed symptoms acquire a mechanism and mechanisms are actionable in a way that reassurance never is.

How the audit changes the protocol, not just the diagnosis

A comprehensive panel is only half the product. The other half is what the clinical model does with it and this is where the audit differs most sharply from the annual screen. When the quarterly read shows fasting insulin elevated and HOMA-IR climbing, the protocol that follows is concrete: a nutrition structure aimed at the insulin axis rather than a generic diet, movement prescriptions weighted toward the work that improves insulin sensitivity, sleep and stress management where the cortisol picture warrants it and where the metabolic picture is severe enough, medication, including branded GLP-1 therapy prescribed against the labs.

The next audit then holds all of it to the same standard. Insulin, HOMA-IR, HbA1c, triglycerides and ApoB are re-read in ninety days and the protocol either earns its continuation or gets revised, because accountability is the difference between a panel and a program. An annual screen produces a conversation. A quarterly audit produces a loop and the loop is where compensation gets reversed before it becomes disease.

FAQ

Is A1c enough to rule out prediabetes? No. A1c is a three-month average and a lagging one, so it can sit in the normal range while insulin resistance is well established. Fasting insulin and HOMA-IR catch the compensation phase earlier.

What is the best test for insulin resistance? Fasting insulin with a HOMA-IR calculation is the most informative starting pair, read alongside HbA1c, the lipid panel with ApoB and hs-CRP. No single marker is a diagnosis and the panel is read as one system.

How often should metabolic labs be checked? Quarterly is the cadence at which metabolic markers actually move and the one our Biomarker Audit runs on. An annual screen reads a quarterly problem once a year.

Does insurance cover advanced metabolic labs? Standard panels are usually covered. Advanced markers like ApoB, Lp(a) and fasting insulin are often not, which is one reason the system under-orders them. Our membership includes them in the quarterly audit inside the flat fee.

Can prediabetes be reversed? Often yes and the evidence is strongest when the compensation phase is caught early. Weight, activity, sleep and, where indicated, medication all move the markers and the quarterly audit is what proves whether they moved.

Does the membership fee include the labs? Yes. Four comprehensive Biomarker Audits a year are inside the flat $299 monthly fee, with a two month commitment at the start paid as a single $598 charge. Additional labs beyond the quarterly cadence are billed at pass-through cost.

Related Guides

References

  1. CDC: Prediabetes prevention and national prevalence. 2026. www.cdc.gov/diabetes/prevention-type-2/prediabetes-prevention.html